Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis

Abstract Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to info...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, Peter D. Arkwright, Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah A. Levit
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Adis, Springer Healthcare 2023-09-01
سلاسل:	Dermatology and Therapy
الموضوعات:	Atopic dermatitis Children Dupilumab Eczema Efficacy Long-term
الوصول للمادة أونلاين:	https://doi.org/10.1007/s13555-023-01016-9
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!